Exchange: NASDAQ·Updated 02:06 PM EDT
QURE logo

QUREuniQure NV

$48.14
$0.905
(1.84%)
Today
EarningsJul 29
Mkt Cap$3.07B
Vol3.25M
News
all
press releases
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.
Zacks
News Placeholder
More News
News Placeholder
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
Zacks
News Placeholder
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks
News Placeholder
Technological Innovations to Wage War Against Some of Medicine's Toughest Diseases
The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. $NTHI, $QURE, $ICCM, $CLPT, $ELTX, $AZTR
24-7 Market News
News Placeholder
QURE Stock Surges Over 70% After FDA Softens Stance On Huntington’s Disease Gene Therapy
uniQure said that the U.S. Food and Drug Administration is willing to consider three years of data as the primary basis for a biologics license application of AMT-130.
Stocktwits
News Placeholder
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message...
Yahoo! Finance: News
News Placeholder
REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief
The New York Times reported that Makary’s departure was driven in large part by his strong opposition to the administration’s decision to authorize fruit-flavored e-cigarettes.
Stocktwits
News Placeholder
REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary
The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.
Stocktwits
News Placeholder
uniQure Q1 Earnings Call Highlights
uniQure (NASDAQ:QURE) executives outlined progress and upcoming regulatory milestones for lead Huntington's disease gene therapy candidate AMT-130 during the company's first-quarter 2026 earnings call, while also providing updates across its epilepsy and Fabry programs and reviewing quarterly financ...
MarketBeat
News Placeholder
uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results
uniQure (NASDAQ:QURE - Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.